July and August were busy months, with numerous US companies announcing their latest results. Amid this flurry of earnings reports, you may have overlooked some noteworthy performances. We will highlight some of the blue-chip companies that have demonstrated strong earnings growth and have provided promising guidance.

Eli Lilly (NYSE: LLY)

The world’s largest healthcare company has delivered once again. For the second quarter of 2024 (2Q 2024), Eli Lilly demonstrated why it remains a clear leader in the healthcare industry. Eli Lilly announced a revenue increase of 36.0% year on year, climbing from US$8.3 billion to US$11.3 billion. Even more impressively, net profit surged 68.3% year on year, reaching US$3.0 billion. The company attributed its robust revenue growth to higher sales volumes, driven by the success of its diabetes and cancer drugs. Most notably, Eli Lilly has seen blockbuster demand for its drug, Mounjaro, which is known for enabling “cosmetic weight loss”, despite the company’s attempt to discourage such uses....